APPLICATION OF COMPOUND IN PREPARATION OF INHIBITORY DRUG TARGETING ERBB2 MUTANT Application WO-2022206929-A1 World Intellectual Property Organisation (WIPO) 06 Oct 2022
Antineoplastic combinations with mTOR inhibitor, trastuzumab and/or HKI-272 Grant US-10729672-B2 United States of America 04 Aug 2020
Method for treating gefitinib resistant cancer Grant US-10603314-B2 United States of America 31 Mar 2020
Method for treating gefitinib resistant cancer Grant US-10596162-B2 United States of America 24 Mar 2020
Antineoplastic combinations containing HKI-272 and vinorelbine Grant US-10111868-B2 United States of America 30 Oct 2018
Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinol… Grant US-10035788-B2 United States of America 31 Jul 2018
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quino… Grant US-9630946-B2 United States of America 25 Apr 2017
Antineoplastic combinations containing HKI-272 and vinorelbine Grant US-9511063-B2 United States of America 06 Dec 2016
Treatment regimen utilizing neratinib for breast cancer Grant US-9211291-B2 United States of America 15 Dec 2015
Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quino… Grant US-9139558-B2 United States of America 22 Sep 2015
ANTINEOPLASTIC COMBINATIONS CONTAINING HKI-272 AND VINORELBINE Application RU-2492860-C2 Russian Federation 20 Sep 2013